Interview Archives before 2007

Issue 143: August 4, 2006

143Craig Atwood, Assistant Professor, Department of Medicine, University of Wisconsin, on the Reproductive-Cell Cycle Theory of Aging.

Issue 141: July 21, 2006

141Hiromi Yoshikawa, Chairman and CEO, Otsuka America Pharmaceutical, Inc., on the expansion of Otsuka’s pharmaceutical business in the US.

Issue 140: July 14, 2006:

140Daniel L. Weiner, Senior Vice President, Software Products, Pharsight Corporation, on Pharsight’s CRADA with the FDA and the infrastructure required for modeling and simulation in clinical development.

Issue 139: July 7, 2006

139Garo H. Armen, Chairman and CEO, Antigenics Inc., on Oncophage, an experimental cancer vaccine using heat shock proteins.

Issue 138: June 30, 2006

138Donald A. Berry, Chairman, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, on the use of Bayesian statistical methods in clinical development.

Issue 136: June 16, 2006

136John E. McDonough, Executive Director, Health Care For All, on new legislation designed to reduce the number of people without health insurance in Massachusetts.

Issue 135: June 9, 2006

135Robert J. Feeney, Jr., President & CEO, MedVantx, on his company’s Sample Centers that dispense free generic drug samples.

Issue 134: June 2, 2006

134Dr. Anthony Hayward, Director, Division of Clinical Research Resources, National Center for Research Resources, NIH, on a new Roadmap initiative to promote clinical research.

Issue 133: May 26, 2006

133Dr. Steve E. Phurrough, Director, Coverage & Analysis Group, CMS, on National Coverage Determinations for Part B Drugs in Medicare.

Issue 132: May 19 , 2006

132Dr. Randall S. Stafford, Assistant Professor of Medicine, Stanford Prevention Research Center, on new research in off-label prescribing patterns.

Issue 131: May 12, 2006

131Dr. Bruce Silver, VP of Global Product Development Services in Oncology, PRA International, on issues in cancer drug development.

Issue 129: April 21, 2006

129Dr. John T. Santini, Jr., President, MicroCHIPS, Inc., on implantable devices for drug delivery.

Issue 128: April 13, 2006

128Diana Conmy, Corporate Director of Market Insights at IMS Health, on key developments for the pharmaceutical industry in 2005.

Issue 127: April 7, 2006

127Paul J. Hastings, President and Chief Executive Officer of Oncomed, Inc., on drugs to target cancer stem cells.

Issue 126: March 31, 2006

126Dr. David Sinclair, Associate Professor of Pathology at Harvard Medical School, on the effects of SIR2 on the aging process.

Issue 125: March 24, 2006

125Dr. Abner L. Notkins, Chief of Experimental Medicine for the National Institute of Dental and Craniofacial Research at the NIH, on the use of autoantibodies in predictive medicine.

Issue 124: March 17, 2006

124Michael Valentino, Chief Consultant, PBM Strategic Healthcare Group, VA, on the VA�fs national formulary.

Issue 123: March 10, 2006

123J.D. Kleinke, Chairman & Executive Director, Omnimedix Institute, on obstacles to the development of a viable HIT system.

Issue 121:February 24, 2006

121Dr. Barry Davis, Principal Investigator & Director, ALLHAT Clinical Trials Center, on using the landmark ALLHAT results to change prescribing behavior.

Issue 120: February 17, 2006

120Dr. Gerald Reaven, Professor Emeritus (Active) of Medicine, Stanford University, on insulin resistance syndrome.

Issue 117: January 27, 2006

117Dr. Stanley Ip, Project Leader, and Dr. Peter Bonis, Primary Technical Expert, Tufts-New England Medical Center Evidence-based Practice Center, on the comparative effectiveness of treatments for gastroesophageal reflux disease.

Issue 116: January 20, 2006

116Dr. Timothy Anderson, Senior Pharmaceutical Analyst, Prudential Equity Group, LLC, on pharmaceutical patent expirations in 2006.

Issue 115:January 13, 2006

115Dr. Kazuko Nishikura, Professor, Gene Expression and Regulation Program, The Wistar Institute, on her research into RNA editing and microRNA.

Issue 113: December 22, 2005

113Dr. Alice M. Rivlin, Senior Fellow in Economic Studies, The Brookings Institution, on the fiscal sustainability of Medicare spending.

Issue 112:December 16, 2005

112James M. Karis, President & CEO, Entelos, Inc., on the role of in silico modeling in drug development.

Issue 110: December 2, 2005

110Jerry Avorn, Professor of Medicine, Harvard Medical School, on academic detailing and physician prescribing behavior.

Issue 109: November 18, 2005

109Kenneth I. Kaitin, Director, Tufts Center for the Study of Drug Development, on recent drug output trends.

Issue 108: November 11, 2005

108Joan Alker, Senior Researcher, Georgetown Health Policy Institute, on Florida’s proposed changes to the state Medicaid program.

Issue 107: November 4, 2005

107Joshua Shinoff, Licensing Officer, Office of Technology Licensing, on technology transfer at UC Berkeley.

Issue 105: October 21, 2005

105John A. Scarlett, President and CEO, Tercica, on the company’s newly approved treatment for short stature.

Issue 103: October 7, 2005

103Jean R. Slutsky, Director, Center for Outcomes and Evidence, on MMA provisions affecting the Agency for Healthcare Research and Quality.

Issue 102: September 30, 2005

102Dara A. Corrigan, Partner, Arnold & Porter, on new MMA priorities for the Inspector General’s Office at HHS.

Issue 101: September 23, 2005

101Larry Gold, CEO & Chairman of the Board, SomaLogic, Inc., on the uses of aptamer technology.

Issue 100: September 16, 2005

100Larry D. Sasich, Staff Pharmacist, Public Citizen, on drug safety issues at the FDA.

Issue 99: September 9, 2005

99Mark Heesen,President, National Venture Capital Association, on venture capital financing trends in the biotech industry.

Issue 98: September 2, 2005

98Dr. John A. Gans, EVP and CEO, American Pharmacists Association, on the role of pharmacists in improving drug safety.

Issue 97: August 26, 2005

97David Largaespada,Associate Professor, University of Minnesota Cancer Center, on a new method of cancer-gene identification using the Sleeping Beauty transposon.

Issue 96: August 12, 2005

96Makoto Nishimura, President and CEO of Astellas Pharma US, Inc. on Astellas’s strategy in U.S. market.

Issue 93: July 22, 2005

93Sharon Anglin Treat, Executive Director, National Legislative Association on Prescription Drug Prices, on state-level initiatives to reduce prescription drug prices..

Issue 92: July 15, 2005

92Dr. Moriya Tsuji, Associate Professor, Aaron Diamond AIDS Research Center, Rockefeller University, on the discovery of new antigens that bind to the CD1d receptor and activate NKT cells.

Issue 91: July 8, 2005

91Larry McComber, VP Contract and Program Services, Novation LLC, on GPO contracting for prescription drugs.

Issue 90: July 1, 2005

90Robert K. Passikoff, Founder and President, Brand Keys, Inc., on DTC corporate and product brand promotion.

Issue 89: June 24, 2005

89Jeffrey I.D. Lewis, Partner, Patterson Belknap Webb & Tyler LLP, on the impact of the Integra v. Merck decision on pharmaceutical research.

Issue 88: June 17, 2005

88Shabbir Dahod, President and CEO, SupplyScape Corporation, on developing an electronic pedigree for the pharmaceutical supply chain.

Issue 86: May 27, 2005

86Michael Rosen, Chairman and CEO, Immune Cell Therapy, Inc., on the life sciences hub in the Midwest.

Issue 84: May 13, 2005

84Gary Zammit, President and CEO, Clinilabs, Inc., on progress in developing treatments for sleep disorders.

Issue 80: April 15, 2005

80Frank M. Rapoport, Partner, McKenna Long & Aldridge LLP, on the BioShield legislation and the development of a biodefense industry.

Issue 78: April 1, 2005

78Steve Powell, Vice President of Worldwide Sales, Phase Forward, Incorporated, on the use of electronic data capture in clinical trials

Issue 77: March 25, 2005

77Christopher Watts, Staff Fellow, Center for Drug Evaluation and Research, FDA, on moving to real time release with PAT.

Issue 76: March 18, 2005

76Daniel Devine, President and CEO, Acceptys, Inc., on shifting from humanized to fully-human monoclonal antibodies.

Issue 75: March 11, 2005

75Alton C. Morgan, Chairman and President, InNexus Biotechnology, Inc., on the development of SuperAntibodies.

Issue 73: February 25, 2005

73Paul Cusenza, Vice President, Alliance Management, Perlegen Sciences, Inc., on Perlegen’s approach to high-density, whole genome SNP genotyping.

Issue 72: February 18, 2005

72Derek Guyton, Principal, Mercer Human Resources Consulting, on how employer-sponsored retiree drug benefits are being affected by the MMA.

Issue 69: January 28, 2005

69Steven H. Sklar, Partner, Leydig, Voit & Mayer, Ltd., on the Teva v. Pfizer decision on declaratory judgment actions.

Issue 68: January 21, 2005

68Vera Hassner Sharav, President, Alliance for Human Research Protection, on how industry practices in clinical trials have led to an erosion of public trust.

Issue 65: December 24, 2004

65Maxine Gowen, Managing Partner, SR One, on the investment approach of a venture capital subsidiary of a major pharmaceutical company.

Issue 64: December 17, 2004

64Jennifer Covich Bordenick, MA, Director of Strategic Programs, eHealth Initiative, on the adoption of e-prescribing.

Issue 63: December 10, 2004

63John Santa, Medical Director of the Center for Evidence-based Policy at Oregon Health and Science University, on state initiatives to create a transparent drug evaluation system for more cost-effective drug spending.

Issue 61: November 19, 2004

61J. David Haddox, Vice President, Risk Management & Health Policy, Purdue Pharma, on a government-aided, multifaceted approach to reduce the potential for abuse of prescription pain treatments.

Issue 59: November 5, 2004

59Mark Merritt, President and CEO, Pharmaceutical Care Management Association, on the role of pharmacy benefit managers in the Medicare prescription drug benefit.

Issue 57: October 22, 2004

57Joseph S. McCracken, Vice President, Business Development, Genentech, Inc., on Genentech’s approach to R&D and commercialization partnerships.

Issue 56: October 15, 2004

56Kathleen Jaeger, President and CEO, Generic Pharmaceutical Association, on the scientific advancements facilitating regulatory evaluations of biogenerics.

Issue 55: October 8, 2004

55Richard C. Aulatta, President, R.C. Auletta and Co., on Merck’s handling of the Vioxx recall.

Issue 52: September 17, 2004

52Michael Krensavage, Senior Vice President, Equity Research, Raymond James & Associates, on Schering-Plough’s turnaround strategy.

Issue 51: September 10, 2004

51Richard D. Kelly, Senior Partner, Oblon, Spivak, McClelland, Maier & Neustadt, P.C., on issues relating to authorized generics.

Issue 49: August 20, 2004

49Jeffrey Aronin, Founder, President and COO, Ovation Pharmaceuticals, on Ovation’s niche market business strategy.

Issue 48: August 13, 2004

48Nobuya Oka, Executive Vice President, Takeda Pharmaceuticals North America, on Takeda’s strategy in the U.S. market.

Issue 47: August 6, 2004

47Reeta Roy, Vice President, Global Citizenship and Policy, Abbott Laboratories, on Abbott’s AIDS initiatives in developing countries.

Issue 45: July 23, 2004

45Kevin Outterson, Associate Professor of Law, West Virginia University, on the impact of the Australia-U.S. Free Trade Agreement on the market for pharmaceuticals.

Issue 44: July 16, 2004

44Vamsi K. Mootha, M.D., Assistant Professor, Harvard Medical School, on the team-science approach to biomedical research.

Issue 43: July 9, 2004

43Michael M. Gottesman, M.D., Deputy Director for Intramural Research, NIH, on intramural research at the NIH.

Issue 42: July 2, 2004

42Barry Greene, Chief Operating Officer, Alnylam Pharmaceuticals, on RNAi therapeutics.

Issue 41: June 25, 2004

41Carl B. Feldbaum, President, Biotechnology Industry Organization (BIO), on the development of BIO and the biotech industry during his tenure.

Issue 40: June 18, 2004

40Donald W. Moran, President, The Moran Company, on New York Attorney General Eliot Spitzer’s fraud suit against GlaxoSmithKline.

Issue 37: May 28, 2004

37Frank F. Bilstein (Left), Partner, and Razmic S. Gregorian, Jr. (Right), Director, Simon-Kucher & Partners, on the impact of the Medicare legislation on the environment for drug pricing in the U.S.

Issue 36: May 21, 2004

36Robert Monaghan (Left), CEO, and Lawrence K. Cohen (Right), Vice Chairman, Zyomyx Inc., on the use of protein chips in drug development.

Issue 35: May 14, 2004

35Viren Mehta, Managing Member, Mehta Partners LLC, on the merits of the Sanofi-Aventis merger .

Issue 34: May 7, 2004

34John Rother, Director of Policy and Strategy, AARP, on the new Medicare drug discount cards and legislative reform priorities for Medicare.

Issue 32: April 23, 2004

32Merrill Goozner, Journalist and Project Director, Center for Science in the Public Interest, on his new book, The $800 Million Pill.

Issue 31: April 16, 2004

31Josef H. von Rickenbach, Chairman and CEO, PAREXEL International, on current trends in clinical development.

Issue 30: April 9, 2004

30Scott Gottlieb, M.D.,Director of Medical Policy Development, FDA, on Mark McClellan’s tenure at the FDA. .

ssue 29: April 2, 2004

29Wayne Koberstein, Contributing Editor, Contract Pharma, on globalization, consolidation, and pharmaceutical market strategies.

Issue 28: March 26, 2004

28Barbara Yanni, Chief Licensing Officer and Vice President, Merck & Co., Inc., on Merck’s in-licensing activities.

Issue 27: March 19, 2004

27Steven Rauscher, President and CEO, Genome Therapeutics, on the market launch of Factive.

Issue 26: March 12, 2004

26Richard Trabert, Public affairs consultant and faculty member at Boston College’s Center for Corporate Citizenship, on social initiatives in the pharmaceutical industry.

Issue 25: March 5, 2004

25Lowell E. Schnipper, M.D., Harvard Medical School Professor and Chief of Hematology and Oncology at Beth Israel Deaconess Medical Center, on synergies between new and existing treatments in oncology.

Issue 24: February 27, 2004

24Soichi Matsuno, Chairman, Eisai Inc., on Eisai’s strategy in the U.S. market.

Issue 23: February 20, 2004

23Donald O. Beers, Partner, Arnold & Porter, on polymorph patents.

Issue 22: February 13, 2004

22Ken Araki, Pharmaceutical Industry Global Research Director, Nomura Securities International, on the forces shaping change in the pharmaceutical industry.

Issue 21: February 6, 2004

21Jean-Paul Modde, Group President, Dendrite International, Inc., on new trends in CRM in the pharmaceutical industry.

Issue 19: January 23, 2004

19Kevin Goodno, Commissioner, Minnesota Department of Human Services, on Minnesota’s initiatives toward prescription drug importation.

Issue 18: January 16,2004

18Preston Henske, Vice President, Bain & Company, on building a new business model in the pharmaceutical industry.

Issue 15: December 12, 2003

15Kenneth S. Abramowitz, Senior Advisor, The Carlyle Group, on the impact of Medicare reforms on the HMO industry.

Issue 14: December 5, 2003

14Anthony Robbins, M.D., Professor of Public Health, Tufts University School of Medicine, on Medicare reform in historical perspective.

Issue 12: November 21, 2003

12Louis M. Solomon, Partner, Proskauer Rose LLP, on Hatch-Waxman reforms.

Issue 11: November 14, 2003

11Sharon Treat, Senate Majority Leader, State of Maine, on Maine’s initiatives to lower the cost of prescription drugs.

Issue 10: November 7, 2003

10Nick Naclerio, President, ParAllele BioSciences, on pushing the boundaries of high-throughput SNP genotyping.

Issue 9: October 31, 2003

9Vibeke Strand, M.D., Adjunct Clinical Professor, Division of Immunology, Stanford University, on new treatment therapies for rheumatiod arthritis.

Issue 7: October 17, 2003

Christopher D. Hook, Director for RFID Market Development & Deborah H. Murphy, Life Sciences Market Development Manager, Zebra Technologies, on technologies for pharmaceutical supply chains.

Issue 6: October 10, 2003

6Brian G. Atwood, Managing Director, Versant Ventures, on biotech venture capital investing and market cycles.

Issue 5: October 3, 2003

5Glenn Rice, Vice President for Biopharmaceutical Sciences, SRI International, on bridging the gap from university research labs to clinical trials.

Issue 4: September 26, 2003

Eric Lindsey, Vice President for Business Development, PDI Inc., on salesforce outsourcing.

Issue 3: September 19, 2003

Jack Trout, President, Trout & Partners, Ltd., on product positioning through DTC advertising.

Issue 2: September 12, 2003

Tom Heyman, Executive Vice President for Business Development, Johnson & Johnson, on J&J’s in-licensing activities.

Issue 1: September 5, 2003

Paula Campbell Evans, Partner, Palmer & Dodge LLP, on the regulatory prospects for generic biologics.

Copyright © MSAPR Partners - Site Development AlpineWeb Design